PARIS – May 23, 2018 – A novel non-hyperemic index of coronary stenosis severity called resting full-cycle ratio (RFR) was found to be diagnostically equivalent to instantaneous wave-free ratio (iFR) in the VALIDATE RFR study. The results were presented today at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions, by Ziad A. Ali, MD, DPhil, and simultaneously published in EuroIntervention.

RFR, which is not yet approved for use in the United States, measures the ratio of the pressure at the point of absolute lowest resting diastolic pressure (Pd) compared to aortic pressure (Pa) during the cardiac cycle. It measures the pressure difference in the cardiac cycle without the need for an ECG and regardless of timing within the cardiac cycle. iFR is measured during a specific segment of diastole, the “wave-free period” where it is assumed that coronary flow is maximal and resistance minimized.

“Results from the VALIDATE RFR study indicate that RFR could be used as an alternative to iFR to measure blood flow and has the potential to identify pressure-based stenosis severity independent of timing within the cardiac cycle,” said Dr. Ali, Director of the Angiographic Core Laboratory at the CRF Clinical Trials Center and Director of Invasive Imaging and Physiology at the Center for Interventional Vascular Therapy at NewYork-Presbyterian/Columbia University Irving Medical Center. “Additional research is needed to determine whether these differences will translate to superior clinical utility.”

Data from the VALIDATE RFR study were analyzed at the CRF Clinical Trials Center.

About CRF

The Cardiovascular Research Foundation (CRF) is a nonprofit research and educational organization dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For over 25 years, CRF has helped pioneer innovations in interventional cardiology and educate doctors on the latest treatments for heart disease.

The CRF Clinical Trials Center (CTC) is a distinguished academic research organization which has contributed to key advances in the treatment of cardiovascular disease and played an essential role in bringing new devices and therapies to patients. The CTC specializes in trial conception and design, imaging core laboratories, clinical event adjudication and data safety monitoring, as well as biostatistical analysis and data management.


Press Contacts

Irma Damhuis
Director, External Relations
Tel: 646-434-4690

Judy Romero
Program Manager, External Relations
Tel: 646-434-4608